<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1758">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138276</url>
  </required_header>
  <id_info>
    <org_study_id>Guangdong Women and Children H</org_study_id>
    <nct_id>NCT05138276</nct_id>
  </id_info>
  <brief_title>Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates</brief_title>
  <acronym>ACBMNC</acronym>
  <official_title>Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Women and Children Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Women and Children Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-clinical animal studies provide robust evidence regarding the beneficial effect of stem&#xD;
      cells for intestinal disease.&#xD;
&#xD;
      This single-center, randomized, controlled, blinded trial assessed the effect of a single&#xD;
      intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing NEC in preterm&#xD;
      neonates,and influence on growth and development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and settings:&#xD;
&#xD;
      This study will be a randomized, placebo-controlled, double-blinded, single-center trial. A&#xD;
      total of 45 singleton preterm infants (GS&lt;33 weeks) of fulfilling the eligibility criteria&#xD;
      will be enrolled. According to the infusion of umbilical cord blood mononuclear cells and&#xD;
      equal dose placebo, the premature infants were divided into infusion group and control group.&#xD;
      The two groups were matched with gender, gestational age and birth weight as stratified&#xD;
      variables and 1:2 (the gender was the same, and the difference between gestational age and&#xD;
      birth weight was the smallest).&#xD;
&#xD;
      Trial treatment methods: Study design and settings:&#xD;
&#xD;
      This study will be a randomized, placebo-controlled, double-blinded, single-center trial. A&#xD;
      total of 30 pairs of monozygotic twins fulfilling the eligibility criteria will be enrolled.&#xD;
      Subsequently, one baby of each twin will be randomly divided into the ACBMNC infusion group&#xD;
      or control (placebo) group.&#xD;
&#xD;
      Trial treatment methods:&#xD;
&#xD;
      Soon after the preterm infant was deliveried, written consent was signed by the parents, and&#xD;
      autologous cord blood infusion was applied to the baby in addition to routine treatment.&#xD;
      Those assigned to the ACBMNC group received an infusion of ACBMNC . Those in control group&#xD;
      received an infusion of a placebo solution. Informed consent before birth is signed. Preterm&#xD;
      infants in the ACBMNC infusion group will have their umbilical cord blood collected after&#xD;
      birth, and then their umbilical cord blood will be separated through Guangdong Province&#xD;
      umbilical cord blood Bank to obtain mesenchymal stem cells. Within 24h after birth, ACBMNC&#xD;
      group received an infusion of mesenchymal stem cells timely, while control (placebo) group&#xD;
      received an infusion of a placebo solution which is normal saline with the same volume. Cell&#xD;
      dose for all patients was targeted at 5×107 cells per kilogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Triple (Participant, Care Provider, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of Necrotizing enterocolitis in hospitalization</measure>
    <time_frame>up to one year</time_frame>
    <description>NEC rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The severity of Necrotizing enterocolitis</measure>
    <time_frame>up to one year</time_frame>
    <description>severe NEC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of feeding intolerance</measure>
    <time_frame>up to one year</time_frame>
    <description>Other outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of other intestinal disease</measure>
    <time_frame>up to one year</time_frame>
    <description>Other outcomes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Neonatal Necrotizing Enterocolitis</condition>
  <condition>Growth and Development</condition>
  <condition>Preterm Infants</condition>
  <condition>Nutrition</condition>
  <arm_group>
    <arm_group_label>Autologous cord blood mononuclear cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy 24 hours after birth ,dose is 50 million cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride infusion 24 hours after birth</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Umbilical Cord Blood Mononuclear Cells Therapy</intervention_name>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC</description>
    <arm_group_label>Autologous cord blood mononuclear cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium Chloride</intervention_name>
    <description>0.9% Sodium Chloride in control group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (1) born at the study hospital; (2) singleton birth; (3) 26&lt;GA &lt;32&#xD;
        weeks; (4) free of severe congenital anomalies or genetic syndromes;&#xD;
&#xD;
        Exclusion criteria： (1) mothers with clinical chorioamnionitis; (2) the mother was opsitive&#xD;
        for hepatitis B (HBsAg and/or HBeAg), hepatitis C (anti-HCV), syphilis, HIV (anti-HIV-1 and&#xD;
        -2), and IgM against cytomegalovirus, rubella, toxoplasma, and herpes simplex viruses; (3)&#xD;
        consent was not obtained from the parents or guardians; and (4) after processing, UCB cells&#xD;
        were not available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Yang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Women and Children Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiayu Miao, MD</last_name>
    <phone>13560324100</phone>
    <email>sara930924@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jie Yang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>511400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yang, PHD</last_name>
      <phone>39151777</phone>
      <phone_ext>020</phone_ext>
      <email>jasjie_yang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 Jul 25;122(4):491-8. doi: 10.1182/blood-2013-02-453175. Epub 2013 May 14. Review.</citation>
    <PMID>23673863</PMID>
  </reference>
  <reference>
    <citation>Mezey É, Nemeth K. Mesenchymal stem cells and infectious diseases: Smarter than drugs. Immunol Lett. 2015 Dec;168(2):208-14. doi: 10.1016/j.imlet.2015.05.020. Epub 2015 Jun 4. Review.</citation>
    <PMID>26051681</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Women and Children Hospital</investigator_affiliation>
    <investigator_full_name>yang jie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Necrotizing enterocolitis</keyword>
  <keyword>Preterm infants</keyword>
  <keyword>Prevention</keyword>
  <keyword>cord blood mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

